MCID: ESN020
MIFTS: 54

Eosinophilic Granulomatosis with Polyangiitis

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Eosinophilic Granulomatosis with Polyangiitis

MalaCards integrated aliases for Eosinophilic Granulomatosis with Polyangiitis:

Name: Eosinophilic Granulomatosis with Polyangiitis 54 60 38
Churg-Strauss Syndrome 54 60 74
Granulomatous Allergic Angiitis 54 60
Egpa 54 60
Allergic Angiitis and Granulomatosis 54
Allergic Granulomatous and Angiitis 54
Churg-Strauss Vasculitis 54
Allergic Granulomatosis 54
Css 54

Characteristics:

Orphanet epidemiological data:

60
eosinophilic granulomatosis with polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),<1/1000000 (Sweden),1-9/100000 (France),1-9/100000 (Sweden),<1/1000000 (United Kingdom),1-9/100000 (Norway),<1/1000000 (Spain),1-9/100000 (Australia),1-9/1000000 (Europe),1-9/100000 (Worldwide),<1/1000000 (Norway),1-9/1000000 (Germany),1-9/1000000 (Lithuania),1-9/1000000 (France),1-9/100000 (Germany),1-9/100000 (Japan); Age of onset: Adolescent,Adult,Elderly; Age of death: adolescent,adult,elderly,young Adult;

Classifications:



Summaries for Eosinophilic Granulomatosis with Polyangiitis

NIH Rare Diseases : 54 Eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small to medium sized blood vessels (vasculitis). The inflamed vessels can affect various organ systems including the lungs, gastrointestinal tract, skin, heart and nervous system. The exact cause of eosinophilic granulomatosis with polyangiitis is unknown, but it is thought to be an autoimmune disorder. Treatment may involve the use of glucocorticoids (steroids) and/or other immunosuppressive therapies. As of December 2017, mepolizumab (Nucala) became the first therapy approved specifically to treat eosinophilic granulomatosis with polyangiitis. When added to traditional steroid or immunosuppressive therapy, mepolizumab has been found to increase remission rate and time in remission for 50% of people with eosinophilic granulomatosis with polyangiitis.

MalaCards based summary : Eosinophilic Granulomatosis with Polyangiitis, also known as churg-strauss syndrome, is related to granulomatosis with polyangiitis and churg-strauss syndrome. An important gene associated with Eosinophilic Granulomatosis with Polyangiitis is FCGR3B (Fc Fragment Of IgG Receptor IIIb), and among its related pathways/superpathways is Phagosome. The drugs Cyclophosphamide and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include heart, skin and lung, and related phenotypes are weight loss and peripheral neuropathy

Wikipedia : 77 Eosinophilic granulomatosis with polyangiitis (EGPA), also known as allergic granulomatosis, is an... more...

Related Diseases for Eosinophilic Granulomatosis with Polyangiitis

Diseases related to Eosinophilic Granulomatosis with Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 granulomatosis with polyangiitis 30.6 FCGR3B IL27 MPO
2 churg-strauss syndrome 11.8
3 allergic angiitis 11.8
4 anca-associated vasculitis 11.8
5 coffin-siris syndrome 1 11.4
6 autoimmune lymphoproliferative syndrome 11.3
7 granulomatous angiitis 10.6
8 glomerulonephritis 10.6
9 vasculitis 10.6
10 branch retinal artery occlusion 10.6
11 retinal artery occlusion 10.6
12 wells syndrome 10.6
13 central retinal artery occlusion 10.5
14 asthma 10.5
15 neuropathy 10.5
16 myocarditis 10.4
17 hypereosinophilic syndrome 10.4
18 crescentic glomerulonephritis 10.4
19 hemorrhage, intracerebral 10.4
20 aspergillosis 10.4
21 thrombosis 10.4
22 allergic bronchopulmonary aspergillosis 10.3
23 cholecystitis 10.3
24 cardiac conduction defect 10.3
25 gastroenteritis 10.3
26 acalculous cholecystitis 10.3
27 iga glomerulonephritis 10.3
28 purpura 10.3
29 rapidly progressive glomerulonephritis 10.3
30 dacryoadenitis 10.3
31 systemic polyarteritis nodosa 10.3
32 hepatitis 10.3
33 endocarditis 10.3
34 polyneuropathy 10.3
35 mononeuritis multiplex 10.3
36 peripheral nervous system disease 10.3
37 rere-related disorders 10.3
38 ige responsiveness, atopic 10.2
39 thrombophilia due to thrombin defect 10.2
40 anemia, autoimmune hemolytic 10.2
41 nonarteritic anterior ischemic optic neuropathy 10.2
42 yemenite deaf-blind hypopigmentation syndrome 10.2
43 focal segmental glomerulosclerosis 1 10.2
44 angina pectoris 10.2
45 arthritis 10.2
46 focal segmental glomerulosclerosis 10.2
47 hemolytic anemia 10.2
48 ischemic optic neuropathy 10.2
49 retinal vein occlusion 10.2
50 mononeuropathy 10.2

Graphical network of the top 20 diseases related to Eosinophilic Granulomatosis with Polyangiitis:



Diseases related to Eosinophilic Granulomatosis with Polyangiitis

Symptoms & Phenotypes for Eosinophilic Granulomatosis with Polyangiitis

Human phenotypes related to Eosinophilic Granulomatosis with Polyangiitis:

60 33 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 weight loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0001824
2 peripheral neuropathy 60 33 hallmark (90%) Very frequent (99-80%) HP:0009830
3 sinusitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000246
4 congestive heart failure 60 33 hallmark (90%) Very frequent (99-80%) HP:0001635
5 autoimmunity 60 33 hallmark (90%) Very frequent (99-80%) HP:0002960
6 purpura 60 33 hallmark (90%) Very frequent (99-80%) HP:0000979
7 asthma 60 33 hallmark (90%) Very frequent (99-80%) HP:0002099
8 urticaria 60 33 hallmark (90%) Very frequent (99-80%) HP:0001025
9 vasculitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0002633
10 central nervous system degeneration 60 33 hallmark (90%) Very frequent (99-80%) HP:0007009
11 eosinophilia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001880
12 pulmonary infiltrates 60 33 hallmark (90%) Very frequent (99-80%) HP:0002113
13 hypertension 60 33 frequent (33%) Frequent (79-30%) HP:0000822
14 gait disturbance 60 33 frequent (33%) Frequent (79-30%) HP:0001288
15 dysphagia 60 33 frequent (33%) Frequent (79-30%) HP:0002015
16 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
17 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
18 arthralgia 60 33 frequent (33%) Frequent (79-30%) HP:0002829
19 hypertrophic cardiomyopathy 60 33 frequent (33%) Frequent (79-30%) HP:0001639
20 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
21 abnormality of the pleura 60 33 frequent (33%) Frequent (79-30%) HP:0002103
22 venous thrombosis 60 33 frequent (33%) Frequent (79-30%) HP:0004936
23 hypopigmented skin patches 60 33 frequent (33%) Frequent (79-30%) HP:0001053
24 hematuria 60 33 frequent (33%) Frequent (79-30%) HP:0000790
25 skin rash 60 33 frequent (33%) Frequent (79-30%) HP:0000988
26 abnormal pericardium morphology 60 33 frequent (33%) Frequent (79-30%) HP:0001697
27 tubulointerstitial nephritis 60 33 frequent (33%) Frequent (79-30%) HP:0001970
28 respiratory insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0002093
29 arthritis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001369
30 malabsorption 60 33 occasional (7.5%) Occasional (29-5%) HP:0002024
31 gastroesophageal reflux 60 33 occasional (7.5%) Occasional (29-5%) HP:0002020
32 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0000083
33 proteinuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000093
34 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
35 cranial nerve paralysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0006824
36 subcutaneous nodule 60 33 occasional (7.5%) Occasional (29-5%) HP:0001482
37 acrocyanosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001063
38 myocardial infarction 60 33 occasional (7.5%) Occasional (29-5%) HP:0001658
39 transient ischemic attack 60 33 occasional (7.5%) Occasional (29-5%) HP:0002326
40 hemiplegia/hemiparesis 60 33 occasional (7.5%) Occasional (29-5%) HP:0004374
41 myalgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003326
42 intestinal obstruction 60 33 occasional (7.5%) Occasional (29-5%) HP:0005214
43 glomerulopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0100820
44 hemoptysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002105
45 myocarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0012819
46 endocarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100584
47 cough 60 33 occasional (7.5%) Occasional (29-5%) HP:0012735
48 recurrent intrapulmonary hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0006535
49 papule 60 33 occasional (7.5%) Occasional (29-5%) HP:0200034
50 nasal polyposis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100582

MGI Mouse Phenotypes related to Eosinophilic Granulomatosis with Polyangiitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.13 FCGR3B IL27 MPO
2 immune system MP:0005387 8.8 FCGR3B IL27 MPO

Drugs & Therapeutics for Eosinophilic Granulomatosis with Polyangiitis

Drugs for Eosinophilic Granulomatosis with Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Azathioprine Approved Phase 4,Phase 3,Early Phase 1 446-86-6 2265
3
leucovorin Approved Phase 4,Phase 2 58-05-9 143 6006
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 302-25-0
6
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Not Applicable 2921-57-5
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
10
Mycophenolic acid Approved Phase 4 24280-93-1 446541
11
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
13
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Not Applicable 2920-86-7
14 Antimetabolites Phase 4,Phase 3,Phase 2
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Protective Agents Phase 4,Phase 3,Phase 1,Not Applicable
22 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Not Applicable
24 Folate Phase 4,Phase 2
25 Vitamin B Complex Phase 4,Phase 2
26 Folic Acid Antagonists Phase 4,Phase 2
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Prednisolone acetate Phase 4,Phase 3,Not Applicable
29 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
31 Vitamin B9 Phase 4,Phase 2
32 Dermatologic Agents Phase 4,Phase 2,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
35 Methylprednisolone Acetate Phase 4,Phase 3,Not Applicable
36 Anti-Infective Agents Phase 4,Not Applicable
37 Antiemetics Phase 4,Phase 3,Not Applicable
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
41 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
42 Antibiotics, Antitubercular Phase 4
43 Antitubercular Agents Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
47 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
48 Pharmaceutical Solutions Phase 3
49 Immunoglobulins, Intravenous Phase 3
50 Rho(D) Immune Globulin Phase 3

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
2 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
3 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
4 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
5 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
6 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
7 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
8 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Active, not recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
9 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
10 Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Unknown status NCT03010436 Phase 2 Benralizumab
11 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
12 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
13 Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
14 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
15 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
16 Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Recruiting NCT02947945 Phase 2 Reslizumab
17 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
18 Rituxan in Churg Strauss Syndrome With Renal Involvement Terminated NCT00424749 Phase 2 Rituximab;Prednisone
19 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
20 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
21 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
22 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
23 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
24 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Not Applicable Infliximab;Rituximab
25 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
26 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
27 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
28 Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
29 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
30 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
31 Survey of Patients With Idiopathic Orbital Inflammation Syndrome Completed NCT01443000
32 Eosinophilic Granulomatosis With Polyangiitis Cohort Recruiting NCT03036670
33 Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Recruiting NCT00315380
34 Pediatric Vasculitis Initiative Recruiting NCT02006134
35 VCRC Tissue Repository Recruiting NCT02967068
36 Vasculitis Pregnancy Registry Recruiting NCT02593565
37 One-Time DNA Study for Vasculitis Recruiting NCT01241305
38 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
39 Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Recruiting NCT03698071 Not Applicable
40 Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Recruiting NCT03373045
41 NUCALA® Special Drug Use Investigation (EGPA, Long-term) Active, not recruiting NCT03557060 Nucala
42 Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Active, not recruiting NCT01862068
43 VCRC Patient Contact Registry Patient-Reported Data Validation Study Enrolling by invitation NCT02190942
44 Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome Terminated NCT02728271 Early Phase 1

Search NIH Clinical Center for Eosinophilic Granulomatosis with Polyangiitis

Genetic Tests for Eosinophilic Granulomatosis with Polyangiitis

Anatomical Context for Eosinophilic Granulomatosis with Polyangiitis

MalaCards organs/tissues related to Eosinophilic Granulomatosis with Polyangiitis:

42
Heart, Skin, Lung, T Cells, Neutrophil, Colon, Kidney

Publications for Eosinophilic Granulomatosis with Polyangiitis

Articles related to Eosinophilic Granulomatosis with Polyangiitis:

(show top 50) (show all 1178)
# Title Authors Year
1
Chronic pulmonary aspergillosis may cause eosinophilic granulomatosis with polyangiitis via allergic bronchopulmonary aspergillosis. ( 30800324 )
2019
2
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2019
3
Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. ( 30652675 )
2019
4
Massive Myocardial Necrosis due to Churg-Strauss Syndrome. ( 29884587 )
2019
5
Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature. ( 30134390 )
2019
6
Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature. ( 30179138 )
2019
7
Immunoglobulin G4-Related Disease Presenting with Clinical Similarity to Churg-Strauss Syndrome. ( 30772966 )
2019
8
Churg-strauss syndrome: clinical case and its feautures. ( 31055564 )
2019
9
Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: A case report. ( 30603598 )
2019
10
Usefulness of Cardiac Magnetic Resonance in the Diagnosis of Löffler Endocarditis Secondary to Eosinophilic Granulomatosis with Polyangiitis. ( 30146590 )
2019
11
Endothelial dysfunction in patients with eosinophilic granulomatosis with polyangiitis. ( 30132147 )
2019
12
Eosinophilic granulomatosis with polyangiitis mimicking peripheral T-cell lymphoma, not otherwise specified. ( 30153088 )
2019
13
Sputum Antineutrophil Cytoplasmic Antibodies in Serum Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis with Polyangiitis. ( 30179583 )
2019
14
Sputum Antineutrophil Cytoplasmic Antibodies in Eosinophilic Granulomatosis with Polyangiitis. Time to Start Sampling the Right Compartment? ( 30257095 )
2019
15
C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. ( 30317003 )
2019
16
An Atypical Case of Non-asthmatic Eosinophilic Granulomatosis with Polyangiitis Finally Diagnosed by Tissue Biopsy. ( 30449779 )
2019
17
Flare of eosinophilic granulomatosis with polyangiitis related to pregnancy: Case report and review of the literature. ( 30456168 )
2019
18
Non-asthmatic and HCV-seropositive eosinophilic granulomatosis with polyangiitis complicated by multiple intracerebral haemorrhages: a case study. ( 30499447 )
2019
19
Pregnancy in a patient with eosinophilic granulomatosis with polyangiitis. ( 30634882 )
2019
20
A Perianal Mass Associated With Eosinophilic Granulomatosis With Polyangiitis: Challenge. ( 30640763 )
2019
21
Eosinophilic granulomatosis with polyangiitis in a continuous flow left ventricular assist device patient: a case report and review of literature. ( 30684748 )
2019
22
IgG4-Related Disease and Eosinophilic Granulomatosis with Polyangiitis: Similarity or Coexistence? ( 30772965 )
2019
23
Childhood-Onset Eosinophilic Granulomatosis with Polyangiitis with a Vulvar Granuloma: A Case Report and Review of the Literature. ( 30904627 )
2019
24
Anti-neutrophil cytoplasmic antibody-positive eosinophilic granulomatosis with polyangiitis: can it cause membranous nephropathy? ( 30907692 )
2019
25
Multiple Distinctive Demyelinating Lesions Caused by Eosinophilic Granulomatosis With Polyangiitis: Case Report and Literature Review. ( 30930835 )
2019
26
Successful control of severe eosinophilic granulomatosis with polyangiitis in a pregnancy and perinatal period: A use of mepolizumab. ( 30932239 )
2019
27
Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis. ( 30941214 )
2019
28
P-ANCA negative eosinophilic granulomatosis with polyangiitis. ( 30989049 )
2019
29
Eosinophilic Granulomatosis with Polyangiitis in a 4-Year-Old Child: Is Montelukast and/or Clarithromycin a Trigger? ( 31029073 )
2019
30
Eosinophilic Granulomatosis with Polyangiitis Manifesting as Recurrent Nasal Polyps and Hemorrhagic Necrotic Bullae: A Rare Disease Successfully Treated with Azathioprine. ( 31043937 )
2019
31
Refractory oral ulcers in eosinophilic granulomatosis with polyangiitis. ( 31050016 )
2019
32
Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis. ( 31056188 )
2019
33
Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. ( 31056661 )
2019
34
Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis. ( 31080020 )
2019
35
Non-infectious aortic and mitral valve vegetations in a patient with eosinophilic granulomatosis with polyangiitis. ( 31092487 )
2019
36
Eosinophilic granulomatosis with polyangiitis: histopathological confirmation despite negative serology. ( 31100285 )
2019
37
Silent acute myocarditis in eosinophilic granulomatosis with polyangiitis. ( 30641540 )
2018
38
Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. ( 30170804 )
2018
39
Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. ( 29857992 )
2018
40
Immunosuppressive therapy ameliorates refractory vasospastic angina, severe pulmonary hypertension, and bronchiolitis in a patient with eosinophilic granulomatosis with polyangiitis: a case report. ( 31020129 )
2018
41
Cardiogenic Shock: An Unusual Initial Presentation of Churg-Strauss Syndrome. ( 29808153 )
2018
42
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome) Complicated by Perforation of the Small Intestine and Cholecystitis. ( 29269641 )
2018
43
Eosinophilic Granulomatosis with Polyangiitis Manifested by Cholecystitis and Mononeuritis Multiplex: A Case Report. ( 29892153 )
2018
44
Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. ( 29393242 )
2018
45
Churg-Strauss syndrome with cardiac involvement: case illustration and contribution of CMR in the diagnosis and clinical follow-up. ( 29459042 )
2018
46
Anaesthetic management and the role of sugammadex in a patient with Churg-Strauss syndrome. ( 29910505 )
2018
47
Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis: Exuberant Classic Clinical Picture of a Rare Disease. ( 30057533 )
2018
48
Coronary artery vasospasm in a patient withChurg-Strauss syndrome. ( 30366890 )
2018
49
Differential Diagnosis of Churg-Strauss Syndrome with Tingling Sensation and Weakness of the Lower Extremities. ( 30719419 )
2018
50
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) masquerading as acute ST-elevation myocardial infarction with complete resolution after immunosuppressive therapy: a case report. ( 31020153 )
2018

Variations for Eosinophilic Granulomatosis with Polyangiitis

Expression for Eosinophilic Granulomatosis with Polyangiitis

Search GEO for disease gene expression data for Eosinophilic Granulomatosis with Polyangiitis.

Pathways for Eosinophilic Granulomatosis with Polyangiitis

Pathways related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 FCGR3B MPO

GO Terms for Eosinophilic Granulomatosis with Polyangiitis

Cellular components related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 8.8 FCGR3B IL27 MPO

Biological processes related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 8.62 FCGR3B MPO

Sources for Eosinophilic Granulomatosis with Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....